Gustavo A. Rosario Benitez

Array ( [id] => 12051251 [patent_doc_number] => 20170327596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'METHOD' [patent_app_type] => utility [patent_app_number] => 15/606789 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9118 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15606789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15422615 [patent_doc_number] => 10544221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Single chain variable fragment CD3 binding proteins [patent_app_type] => utility [patent_app_number] => 15/600264 [patent_app_country] => US [patent_app_date] => 2017-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 21816 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 499 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15600264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17527035 [patent_doc_number] => 11299708 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Methods for selective expansion of gd T-cell populations and compositions thereof [patent_app_type] => utility [patent_app_number] => 15/563830 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 64 [patent_no_of_words] => 60573 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17768198 [patent_doc_number] => 11400116 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Systems and methods for targeting cancer cells [patent_app_type] => utility [patent_app_number] => 16/096248 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 407 [patent_figures_cnt] => 30 [patent_no_of_words] => 50719 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936734 [patent_doc_number] => 20170240884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'IDENTIFICATION OF T CELL TARGET ANTIGENS' [patent_app_type] => utility [patent_app_number] => 15/587636 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 25901 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15587636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12584943 [patent_doc_number] => 20180086810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/585956 [patent_app_country] => US [patent_app_date] => 2017-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15585956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851713 [patent_doc_number] => 20170226205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Therapeutic Use of Anti-CD22 Antibodies for Inducing Trogocytosis' [patent_app_type] => utility [patent_app_number] => 15/492752 [patent_app_country] => US [patent_app_date] => 2017-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 34759 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15492752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17323608 [patent_doc_number] => 11214603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-04 [patent_title] => C3D cellular and acellular vaccines for the prevention and treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/096106 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 45 [patent_no_of_words] => 22351 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18558696 [patent_doc_number] => 11723921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Modulated immunodominance therapy [patent_app_type] => utility [patent_app_number] => 15/486864 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 38 [patent_no_of_words] => 15880 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15486864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949706 [patent_doc_number] => 20170253857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/483704 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17827 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102317 [patent_doc_number] => 20190092834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/092174 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11756094 [patent_doc_number] => 20170202961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION' [patent_app_type] => utility [patent_app_number] => 15/477379 [patent_app_country] => US [patent_app_date] => 2017-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9210 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15850613 [patent_doc_number] => 10640572 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Anti-CD3 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 15/473242 [patent_app_country] => US [patent_app_date] => 2017-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 170 [patent_figures_cnt] => 172 [patent_no_of_words] => 222445 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15473242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13079437 [patent_doc_number] => 10059776 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-28 [patent_title] => Methods for treating conditions associated with MASP-2 dependent complement activation [patent_app_type] => utility [patent_app_number] => 15/471793 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 66 [patent_no_of_words] => 76499 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15471793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949515 [patent_doc_number] => 20170253667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'METHODS FOR INHIBITING FIBROSIS IN A SUBJECT IN NEED THEREOF' [patent_app_type] => utility [patent_app_number] => 15/470647 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 72930 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15470647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821877 [patent_doc_number] => 20170210814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE' [patent_app_type] => utility [patent_app_number] => 15/469839 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 87 [patent_no_of_words] => 47875 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15469839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12022251 [patent_doc_number] => 20170312350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS' [patent_app_type] => utility [patent_app_number] => 15/461020 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 19784 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15461020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963585 [patent_doc_number] => 20170267738 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS' [patent_app_type] => utility [patent_app_number] => 15/460654 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 35774 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15460654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11873615 [patent_doc_number] => 09745372 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-29 [patent_title] => 'TNF binders' [patent_app_type] => utility [patent_app_number] => 15/456824 [patent_app_country] => US [patent_app_date] => 2017-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 13 [patent_no_of_words] => 32047 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15456824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743956 [patent_doc_number] => 20170198029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'SINGLE CHAIN ANTIGEN RECOGNIZING CONSTRUCTS (SCARCS) STABILIZED BY THE INTRODUCTION OF NOVEL DISULFIDE BONDS' [patent_app_type] => utility [patent_app_number] => 15/452019 [patent_app_country] => US [patent_app_date] => 2017-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10400 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15452019 [rel_patent_id] =>[rel_patent_doc_number] =>)